Esophagogastroduodenoscopy and Ileocolonoscopy

  • Massimo Martinelli
  • Caterina Strisciuglio
  • Erasmo Miele
Chapter

Abstract

Endoscopy is an essential tool in the management of inflammatory bowel disease (IBD). To date, upper and lower gastrointestinal endoscopy are both required for the diagnosis of IBD; furthermore, endoscopy is essential for the differential diagnosis between ulcerative colitis (UC) and Crohn’s disease (CD), the assessment of disease location and activity, and the follow-up of disease course. The advent of mucosal healing as a new goal for IBD therapy may further increase the role of endoscopy to assess response to therapy. Ileocolonoscopy still keeps its fundamental role in the surveillance for dysplasia/neoplasia.

Keywords

Inflammatory bowel disease Ulcerative colitis Crohn’s disease Upper GI endoscopy Ileocolonoscopy Pediatrics 

References

  1. 1.
    Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Bousvarous A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–74.CrossRefGoogle Scholar
  3. 3.
    D’Haens G, Rutgeerts P, Geboes K, Vantrappen G. The natural history of esophageal Crohn's disease: three patterns of evolution. Gastrointest Endosc. 1994;40:296–300.CrossRefGoogle Scholar
  4. 4.
    Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.CrossRefGoogle Scholar
  5. 5.
    Nguyen GC, Torres EA, Requeiro M. Inflammatory bowel disease characteristics among Africans, Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–23.CrossRefGoogle Scholar
  6. 6.
    Vind I, Riis L, Jess T, et al. Increasing in incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and county, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274–82.CrossRefGoogle Scholar
  7. 7.
    Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–9.CrossRefGoogle Scholar
  8. 8.
    Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients—characteristics of newly diagnosed patients from the CEDATA-GPGE registry. Dtsch Arztebl Int. 2015;112:121–7.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Levine A, de Bie CL, Turner D, et al. Atypical disease phenotypes in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm Bowel Dis. 2013;19:370–7.CrossRefGoogle Scholar
  10. 10.
    Hummel TZ, ten Kate FJ, Reitsma JB, Benninga MA, Kindermann A. Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. J Pediatr Gastroenterol Nutr. 2012;54(6):753–7.CrossRefGoogle Scholar
  11. 11.
    Paerregaard A. What does the IBD patient hide in the upper gastrointestinal tract? Inflamm Bowel Dis. 2009;15:1101–4.CrossRefGoogle Scholar
  12. 12.
    Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol. 2006;126:365–76.CrossRefGoogle Scholar
  13. 13.
    Ushiku T, Moran CJ, Lauwers GY. Focally enhanced gastritis in newly diagnosed pediatric inflammatory bowel disease. Am J Surg Pathol. 2013;37:1882–8.CrossRefGoogle Scholar
  14. 14.
    Tobin JM, Sinha B, Ramani P, et al. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. J Pediatr Gastroenterol Nutr. 2001;32:443–8.CrossRefGoogle Scholar
  15. 15.
    Castellaneta SP, Afzalna GM, et al. Diagnostic role of upper endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004;39:257–61.CrossRefGoogle Scholar
  16. 16.
    Abdullah BA, Gupta SK, Croffie JN, et al. The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease a 7-year study. J Pediatr Gastroenterol Nutr. 2002;35:636–40. 7.CrossRefGoogle Scholar
  17. 17.
    Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995–1000.CrossRefGoogle Scholar
  18. 18.
    Robert ME, Tang L, Hao LM, et al. Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years. Am J Surg Pathol. 2004;28:183–9.CrossRefGoogle Scholar
  19. 19.
    Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.CrossRefGoogle Scholar
  20. 20.
    Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin N Am. 2012;41:271–90.CrossRefGoogle Scholar
  21. 21.
    deBie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis. 2013;19:378–85.CrossRefGoogle Scholar
  22. 22.
    Rajwal SR, Puntis JW, McClean P, et al. Endoscopic rectal sparing in children with untreated ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004;38:66–9.CrossRefGoogle Scholar
  23. 23.
    Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol. 1993;17:869–75.CrossRefGoogle Scholar
  24. 24.
    Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723–9.CrossRefGoogle Scholar
  25. 25.
    Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–5.CrossRefGoogle Scholar
  26. 26.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.CrossRefGoogle Scholar
  27. 27.
    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–38.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Massimo Martinelli
    • 1
  • Caterina Strisciuglio
    • 2
  • Erasmo Miele
    • 1
  1. 1.Department of Translational Medical Science, Section of PediatricsUniversity of Naples “Federico II”NaplesItaly
  2. 2.Department of Woman, Child and General and Specialized SurgerySecond University of NaplesCasertaItaly

Personalised recommendations